WKRG

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment ...
Fox 5 San Diego

STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and ...

HORSHAM, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and ...
Fox 5 San Diego

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESS Newswire / January 28, 2025 / Dermata Therapeutics, Inc.

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Derma…

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...